Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Ticagrelor is an oral antiplatelet medication that belongs to a class of drugs known as P2Y12 receptor antagonists. Structurally, ticagrelor is a cyclopentyltriazolopyrimidine. Unlike other drugs in the same class, such as clopidogrel and prasugrel, ticagrelor is a direct-acting reversible inhibitor that does not require metabolic activation. It binds to the P2Y12 receptor on platelets, thereby inhibiting ADP-induced platelet aggregation. This mechanism of action is crucial in reducing the risk of thrombotic cardiovascular events such as myocardial infarction and stroke, particularly in patients with acute coronary syndrome (ACS). Ticagrelor is often prescribed in combination with aspirin for dual antiplatelet therapy. Clinical studies have demonstrated its efficacy in improving cardiovascular outcomes compared to other antiplatelet agents.
仅用于科研。不用于诊断过程。未经明确授权不得转售。